Top-Rated StocksTop-RatedNYSE:PHR Phreesia (PHR) Stock Forecast, Price & News $32.28 -0.22 (-0.68%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$31.59▼$33.0850-Day Range$28.01▼$33.8052-Week Range$16.78▼$40.00Volume343,630 shsAverage Volume419,882 shsMarket Capitalization$1.73 billionP/E RatioN/ADividend YieldN/APrice Target$37.64 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Phreesia MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside17.5% Upside$37.92 Price TargetShort InterestBearish5.80% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.04Based on 21 Articles This WeekInsider TradingSelling Shares$834,743 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.82) to ($2.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector323rd out of 981 stocksBusiness Services, Not Elsewhere Classified Industry51st out of 90 stocks 3.4 Analyst's Opinion Consensus RatingPhreesia has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.92, Phreesia has a forecasted upside of 17.5% from its current price of $32.28.Amount of Analyst CoveragePhreesia has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.80% of the float of Phreesia has been sold short.Short Interest Ratio / Days to CoverPhreesia has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Phreesia has recently decreased by 1.69%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPhreesia does not currently pay a dividend.Dividend GrowthPhreesia does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePhreesia has received a 60.31% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Patient flow management systems", "Health care management software", and "Personal health record software" products. See details.Environmental SustainabilityThe Environmental Impact score for Phreesia is -0.60. Previous Next 1.7 News and Social Media Coverage News SentimentPhreesia has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Phreesia this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for PHR on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phreesia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $834,743.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Phreesia is held by insiders.Percentage Held by Institutions92.23% of the stock of Phreesia is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phreesia are expected to grow in the coming year, from ($2.82) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phreesia is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phreesia is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhreesia has a P/B Ratio of 6.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Phreesia (NYSE:PHR) StockPhreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.Read More Receive PHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter. Email Address PHR Stock News HeadlinesJune 7, 2023 | americanbankingnews.comSVB Leerink Weighs in on Phreesia, Inc.'s Q2 2024 Earnings (NYSE:PHR)June 3, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Posts Earnings Results, Beats Expectations By $0.10 EPSJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 3, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Stock Price Up 4.4% on Strong EarningsJune 2, 2023 | msn.comBaird Maintains Phreesia (PHR) Outperform RecommendationJune 2, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Price Target Cut to $40.00June 1, 2023 | msn.comRBC Capital Reiterates Phreesia (PHR) Sector Perform RecommendationJune 1, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Phreesia (PHR) and Ascendis Pharma (ASND)June 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 1, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Phreesia (PHR)June 1, 2023 | msn.comStephens & Co. Reiterates Phreesia (PHR) Overweight RecommendationJune 1, 2023 | msn.comNeedham Reiterates Phreesia (PHR) Buy RecommendationJune 1, 2023 | americanbankingnews.comPhreesia, Inc. (NYSE:PHR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 1, 2023 | finance.yahoo.comPhreesia (PHR) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 31, 2023 | uk.finance.yahoo.comPhreesia Announces First Quarter Fiscal 2024 ResultsMay 31, 2023 | msn.comPhreesia: Q1 Earnings InsightsMay 31, 2023 | msn.comPhreesia FQ1 results beat estimates, co reaffirms FY 2024 revenue guidanceMay 30, 2023 | msn.comPhreesia Q1 2024 Earnings PreviewMay 30, 2023 | msn.comEarnings Preview: PhreesiaMay 29, 2023 | americanbankingnews.comPhreesia (PHR) Scheduled to Post Earnings on WednesdayMay 27, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Trading Down 6.1% Following Analyst DowngradeMay 26, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Price Target Lowered to $40.00 at KeyCorpMay 25, 2023 | msn.comKeybanc Maintains Phreesia (PHR) Overweight RecommendationMay 17, 2023 | finance.yahoo.comPhreesia Recognized as One of Modern Healthcare’s "Best Places to Work in Healthcare" for a Seventh YearMay 16, 2023 | businesswire.comPhreesia’s Hilary Hatch Named a “Disrupter” in PM360’s ELITE 100May 16, 2023 | technews.tmcnet.comPhreesia's Hilary Hatch Named a "Disrupter" in PM360's ELITE 100May 16, 2023 | finance.yahoo.comPhreesia’s Hilary Hatch Named a "Disrupter" in PM360’s ELITE 100See More Headlines PHR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHR Company Calendar Last Earnings5/31/2023Today6/07/2023Next Earnings (Estimated)9/06/2023Fiscal Year End1/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Business services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNYSE:PHR CUSIPN/A CIK1412408 Webwww.phreesia.com Phone(888) 654-7473Fax646-607-1776Employees1,546Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.92 High Stock Price Forecast$43.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+16.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-176,150,000.00 Net Margins-53.89% Pretax Margin-53.71% Return on Equity-53.25% Return on Assets-41.99% Debt Debt-to-Equity Ratio0.03 Current Ratio2.89 Quick Ratio2.89 Sales & Book Value Annual Sales$280.91 million Price / Sales6.16 Cash FlowN/A Price / Cash FlowN/A Book Value$4.92 per share Price / Book6.56Miscellaneous Outstanding Shares53,580,000Free Float50,477,000Market Cap$1.73 billion OptionableNot Optionable Beta0.62 Key ExecutivesChaim IndigChief Executive Officer & DirectorEvan RobertsChief Operating OfficerBalaji GandhiChief Financial OfficerDaniel NathanChief Technology OfficerRussell ThatcherVice President-EngineeringKey CompetitorsMultiPlanNYSE:MPLNAmerican WellNYSE:AMWLHealthEquityNASDAQ:HQYIronwood PharmaceuticalsNASDAQ:IRWDEstablishment LabsNASDAQ:ESTAView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 94,639 shares on 6/1/2023Ownership: 0.287%Capital Impact Advisors LLCSold 6,272 shares on 5/23/2023Ownership: 0.028%Ameriprise Financial Inc.Bought 39,158 shares on 5/22/2023Ownership: 0.073%Putnam Investments LLCBought 36,997 shares on 5/22/2023Ownership: 0.069%New York State Common Retirement FundBought 8,125 shares on 5/18/2023Ownership: 0.118%View All Insider TransactionsView All Institutional Transactions PHR Stock - Frequently Asked Questions Should I buy or sell Phreesia stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PHR shares. View PHR analyst ratings or view top-rated stocks. What is Phreesia's stock price forecast for 2023? 12 Wall Street analysts have issued 12 month price targets for Phreesia's shares. Their PHR share price forecasts range from $30.00 to $43.00. On average, they anticipate the company's stock price to reach $37.92 in the next year. This suggests a possible upside of 17.5% from the stock's current price. View analysts price targets for PHR or view top-rated stocks among Wall Street analysts. How have PHR shares performed in 2023? Phreesia's stock was trading at $32.36 at the beginning of 2023. Since then, PHR shares have decreased by 0.2% and is now trading at $32.28. View the best growth stocks for 2023 here. When is Phreesia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 6th 2023. View our PHR earnings forecast. How were Phreesia's earnings last quarter? Phreesia, Inc. (NYSE:PHR) posted its quarterly earnings results on Wednesday, May, 31st. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.10. The firm had revenue of $83.85 million for the quarter, compared to analyst estimates of $80.64 million. Phreesia had a negative trailing twelve-month return on equity of 53.25% and a negative net margin of 53.89%. During the same period in the prior year, the business earned ($0.99) EPS. What ETFs hold Phreesia's stock? ETFs with the largest weight of Phreesia (NYSE:PHR) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Invesco DWA Healthcare Momentum ETF (PTH), SPDR FactSet Innovative Technology ETF (XITK), BlackRock Future Innovators ETF (BFTR), First Trust Small Cap Growth AlphaDEX Fund (FYC), Invesco DWA SmallCap Momentum ETF (DWAS) and What guidance has Phreesia issued on next quarter's earnings? Phreesia updated its FY 2025 earnings guidance on Sunday, June, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.00 million-$500.00 million, compared to the consensus revenue estimate of $453.08 million. What is Chaim Indig's approval rating as Phreesia's CEO? 172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com. Chaim Indig has an approval rating of 73% among the company's employees. What other stocks do shareholders of Phreesia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA). When did Phreesia IPO? (PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO. What is Phreesia's stock symbol? Phreesia trades on the New York Stock Exchange (NYSE) under the ticker symbol "PHR." Who are Phreesia's major shareholders? Phreesia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (13.34%), BlackRock Inc. (8.42%), Brown Advisory Inc. (6.05%), Credit Suisse AG (3.64%), Granahan Investment Management LLC (2.79%) and Jennison Associates LLC (2.58%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, Charles Kallenbach, Cheryl Pegus, Daniel Nathan, David Linetsky, Edward L Cahill, Edward L Cahill, Evan Roberts, Gillian Munson, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub, Randy Rasmussen and Thomas Altier. View institutional ownership trends. How do I buy shares of Phreesia? Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Phreesia's stock price today? One share of PHR stock can currently be purchased for approximately $32.28. How much money does Phreesia make? Phreesia (NYSE:PHR) has a market capitalization of $1.73 billion and generates $280.91 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($3.07) on an earnings per share basis. How many employees does Phreesia have? The company employs 1,546 workers across the globe. How can I contact Phreesia? Phreesia's mailing address is 432 Park Avenue South 12th Floor, New York NY, 10016. The official website for the company is www.phreesia.com. The company can be reached via phone at (888) 654-7473, via email at investors@phreesia.com, or via fax at 646-607-1776. This page (NYSE:PHR) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phreesia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.